Biocryst Pharmaceuticals (BCRX) Notes Payables (2014 - 2021)

Biocryst Pharmaceuticals has reported Notes Payables for 8 years, with the latest figure at $30.0 million in Q3 2021.

• For the quarter ending Q3 2021, Notes Payables changed 0.37% year-over-year to $30.0 million; the trailing twelve-month figure through Sep 2021 stood at $30.0 million (changed 0.37% YoY), and the FY2020 full-year result was $30.0 million, up 1.49% from the prior year.
• Notes Payables for Q3 2021 stood at $30.0 million, roughly flat from $30.0 million in the prior quarter.
• The five-year high for Notes Payables was $30.0 million in Q4 2020, with the low at $28.4 million in Q1 2017.
• Historically, Notes Payables has averaged $29.3 million across 5 years, with a median of $29.3 million in 2019.
• Annual changes were most pronounced in 2017 — Notes Payables grew 1.57% — and 2021, when it rose 0.37%.
• Biocryst Pharmaceuticals' Notes Payables stood at $28.7 million in 2017, then climbed by 1.53% to $29.1 million in 2018, then increased by 1.51% to $29.6 million in 2019, then increased by 1.49% to $30.0 million in 2020, then changed by 0.0% to $30.0 million in 2021.
• The last three Notes Payables figures came in at $30.0 million (Q3 2021), $30.0 million (Q2 2021), and $30.0 million (Q1 2021), per Business Quant data.